Biomea Fusion (NASDAQ: BMEA) is a clinical-stage diabetes and obesity medicines company developing oral covalent small-molecule drugs, led by icovamenib (BMF-219), a covalent menin inhibitor. The COVALENT program spans Phase 2 trials in type 1 and type 2 diabetes; on August 24, 2026 the company announced completion of enrollment in COVALENT-211 (icovamenib in insulin-deficient type 2 diabetes), and on August 13, 2026 it announced first-patient-dosed in the OPAL study evaluating icovamenib in combination with semaglutide in obesity. The pipeline also includes BMF-650, a Phase 1 GLP-131 candidate for obesity. Incorporated in 2017 and headquartered in San Carlos, California, Biomea Fusion listed on Nasdaq in April 2021.
COVALENT-211 Phase 2 enrollment completed (icovamenib in insulin-deficient type 2 diabetes)
OPAL study first patient dosed (icovamenib + semaglutide in obesity)
Biomea Fusion has shared phase 1 data on its oral GLP-1 prospect, shedding light on a small molecule designed to balance efficacy and gastrointestinal tolerability. Management hailed the data as a launchpad for talks with potential partners, but investors drove down the share price of the cash-str.
Interim Chief Executive Officer and Director
Co-Founder, President, Chief Operating Officer and Director
Chief Development Officer